Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Novartis AG

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NOVARTIS DELIVERED A SOLID SECOND QUARTER, RETURNING TO SALES GROWTH DRIVEN BY CONTINUED MOMENTUM FROM KISQALI, KESIMPTA, SCEMBLIX AND PLUVICTO. WE ARE ENCOURAGED BY THE EARLY TRAJECTORY OF OUR RECENT LAUNCHES, RHAPSIDO IN CSU AND ITVISMA. WE ALSO MADE MEANINGFUL PIPELINE PROGRESS, HIGHLIGHTED BY UPDATED KISQALI OVERALL SURVIVAL DATA IN EARLY BREAST CANCER AND THE FDA ACCELERATED APPROVAL SUBMISSION FOR DEL-ZOTA IN DMD. WE ARE ON TRACK FOR MULTIPLE IMPORTANT READOUTS AHEAD IN THE SECOND HALF, AND REMAIN ON TRACK TO DELIVER OUR FULL-YEAR GUIDANCE AND MID-TERM OUTLOOK.

NOVARTIS DELIVERED SALES GROWTH IN Q2 AND FURTHER ADVANCED THE PIPELINE; FULL-YEAR GUIDANCE REAFFIRMED

BOSTON--(BUSINESS WIRE)--ANTARES THERAPEUTICS, INC. (ANTARES), A BIOTECHNOLOGY COMPANY DEVELOPING FIRST-IN-CLASS PRECISION MEDICINES FOR CANCER AND OTHER SERIOUS DISEASES, TODAY ANNOUNCED A STRATEGIC COLLABORATION WITH NOVARTIS TO DISCOVER, DEVELOP AND COMMERCIALIZE SMALL MOLECULE THERAPIES AGAINST PROMISING BUT HISTORICALLY UNDRUGGABLE ONCOLOGY TARGETS. THE AGREEMENT UNDERSCORES THE PRODUCTIVITY AND BREADTH OF ANTARES' DISCOVERY CAPABILITIES, WHICH HAVE REPEATEDLY DELIVERED DEVELOPMENT CANDI.

ANTARES THERAPEUTICS ENTERS AGREEMENT WITH NOVARTIS TO DISCOVER, DEVELOP AND COMMERCIALIZE FIRST-IN-CLASS CANCER THERAPIES

BASEL, JUNE 12, 2026  NOVARTIS TODAY PRESENTED DATA FROM THE REMIND TRIAL AT THE EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY (EAACI) CONGRESS SHOWING THAT RHAPSIDO (REMIBRUTINIB) MET ITS PRIMARY ENDPOINTS ACROSS THE THREE MOST COMMON CHRONIC INDUCIBLE URTICARIA (CINDU) SUBTYPES, BECOMING THE FIRST-EVER TREATMENT TO DEMONSTRATE EFFICACY IN A GLOBAL PHASE III CINDU CLINICAL TRIAL7. IN THE REMIND TRIAL, HIGHER RATES OF COMPLETE RESPONSES WERE OBSERVED AT WEEK 12, WITH RESPONSES SEEN AS EARLY AS WEEK 2 IN TWO SUBTYPES. THESE RESULTS DEMONSTRATE THAT RHAPSIDO MAY PROVIDE SUSTAINED RELIEF FOR PATIENTS WHOSE DISEASE REMAINS INADEQUATELY CONTROLLED AFTER TREATMENT WITH SECOND-GENERATION H1-ANTIHISTAMINES7. CHRONIC INDUCIBLE URTICARIA (CINDU) IS A FORM OF CHRONIC HIVES IN WHICH EVERYDAY TRIGGERSSUCH AS PRESSURE, HEAT, COLD, OR SUNLIGHTCAN LEAD TO ITCHY WHEALS, AND THERE ARE CURRENTLY NO APPROVED TARGETED TREATMENT OPTIONS, SAID PROF. DR. MED. MARTIN METZ, DEPUTY DIRECTOR, INSTITUTE OF ALLERGOLOGY, CHARITUNIVERSITTSMEDIZIN BERLIN, GERMANY. THE REMIND RESULTS ACROSS THE THREE MOST COMMON CINDU SUBTYPES HIGHLIGHT THE POTENTIAL OF RHAPSIDO AS AN IMPORTANT NEW TREATMENT OPTION FOR PATIENTS WITH SIGNIFICANT UNMET NEED. THE THREE MOST PREVALENT CINDU SUBTYPES ARE SYMPTOMATIC DERMOGRAPHISM (SD), COLD URTICARIA, AND CHOLINERGIC URTICARIA, WITH SD BEING THE MOST COMMON8. NOVARTIS HAS SUBMITTED A SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) TO THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) SEEKING APPROVAL OF RHAPSIDO FOR THE TREATMENT OF SD SUBTYPE AND WILL CONTINUE ADDITIONAL FILINGS TO HEALTH AUTHORITIES GLOBALLY THROUGHOUT 2026. RHAPSIDO IS APPROVED FOR USE IN THE U.S., EUROPEAN UNION, CHINA AND SEVERAL OTHER COUNTRIES FOR THE TREATMENT OF CHRONIC SPONTANEOUS URTICARIA (CSU), IN ADULT PATIENTS WITH INADEQUATE RESPONSE TO H1-ANTIHISTAMINES. RHAPSIDO SIGNIFICANTLY IMPROVES SYMPTOM CONTROL FOR PATIENTS LIVING WITH THE THREE MOST COMMON SUBTYPES OF CHRONIC INDUCIBLE URTICARIA, AND IT 

NOVARTIS REMIND DATA AT EAACI SHOW RHAPSIDO POTENTIAL AS FIRST TARGETED THERAPY FOR CHRONIC INDUCIBLE URTICARIA (CINDU)

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR FORTITUDE STUDY MET PRIMARY AND KEY SECONDARY ENDPOINTS OF REDUCTION IN KHDC1L AND CREATINE KINASE LEVELS, WITH SAFETY PROFILE CONSISTENT WITH PREVIOUS RESULTS DEL-BRAX INDICATES POTENTIAL TO BECOME THE FIRST DISEASE-MODIFYING TREATMENT FOR FSHD, A PROGRESSIVE AND IRREVERSIBLE NEUROMUSCULAR DISEASE AFFECTING APPROXIMATELY 45-87K PEOPLE IN THE US AND EU NOVARTIS PLANS TO ENGAGE GLOBAL REGULATORY AUTHORITIES ON PHASE I/II DATA; PHASE III STUDY CURRENTLY ENROLLING BASEL, JUNE 11, 2026  NOVARTIS ANNOUNCED TODAY THAT THE BIOMARKER COHORT OF THE FORTITUDE PHASE I/II STUDY OF DEL-BRAX MET ITS PRIMARY AND KEY SECONDARY ENDPOINTS, WITH REDUCTIONS IN KHDC1L (CDUX) AND CREATINE KINASE BIOMARKER LEVELS INDICATING BOTH STRONG TARGET ENGAGEMENT AND REDUCTION IN MUSCLE DAMAGE IN PATIENTS WITH FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD).

NOVARTIS DELPACIBART BRAXLOSIRAN (DEL-BRAX) PHASE I/II STUDY IN FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) MEETS PRIMARY BIOMARKER ENDPOINT

BOSTON & GHENT, BELGIUM--(BUSINESS WIRE)--ORIONIS BIOSCIENCES, A PRIVATELY HELD, CLINICAL-STAGE LIFE SCIENCES COMPANY PIONEERING PROXIMITY-INDUCED THERAPEUTIC MODALITIES, TODAY ANNOUNCED A MULTI-YEAR COLLABORATION WITH NOVARTIS TO DISCOVER AND DESIGN MOLECULAR GLUE DRUGS FOR CHALLENGING THERAPEUTIC TARGETS ACROSS MULTIPLE DISEASE AREAS. THE COLLABORATION EXPANDS THE EXISTING RELATIONSHIP BETWEEN THE COMPANIES AND REFLECTS A SHARED COMMITMENT TO UNLOCK THE FULL VALUE OF INDUCED PROXIMITY APPROAC.

ORIONIS BIOSCIENCES ANNOUNCES STRATEGIC COLLABORATION WITH NOVARTIS TO DISCOVER AND DEVELOP MOLECULAR GLUE MEDICINES

BASEL, JUNE 8TH, 2026  NOVARTIS WILL PRESENT DATA FROM 10 ABSTRACTS AT THE EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY (EAACI) CONGRESS 2026, SPANNING RHAPSIDO (REMIBRUTINIB) CLINICAL TRIAL RESULTS AND REAL-WORLD EVIDENCE ON PATIENT BURDEN AND TREATMENT EXPERIENCE. HIGHLIGHTS INCLUDE TWO LATE-BREAKING ORAL PRESENTATIONS; THE PHASE III REMIND TRIAL FOR RHAPSIDO IN CHRONIC INDUCIBLE URTICARIA (CINDU) AND EXTENSION DATA FROM THE PHASE IIIB REMIXED TRIAL IN CHRONIC SPONTANEOUS URTICARIA (CSU). THE RHAPSIDO PRESENTATIONS AT EAACI 2026 EXPAND OUR UNDERSTANDING OF BTK INHIBITION ACROSS MULTIPLE IMMUNE-MEDIATED DISEASES AND PROVIDE EVIDENCE OF ITS POTENTIAL TO MAKE A MEANINGFUL IMPACT FOR PATIENTS WHO CONTINUE TO FACE SIGNIFICANT BURDEN AND LIMITED TREATMENT OPTIONS, SAID ANGELIKA JAHREIS, GLOBAL HEAD, IMMUNOLOGY DEVELOPMENT, NOVARTIS. NOVARTIS WILL PRESENT RHAPSIDO DATA FROM A LONG-TERM EXTENSION TRIAL IN CHRONIC SPONTANEOUS URTICARIA, PHASE III DATA IN THREE TYPES OF CHRONIC INDUCIBLE URTICARIA, AND EARLY PHASE II DOSE-RESPONSE ANALYSIS FOR FOOD ALLERGY  TOGETHER PROVIDING SCIENTIFIC EVIDENCE FOR ITS IMPACT ACROSS NUMEROUS DISEASES. ABSTRACTS ACCEPTED BY EAACI INCLUDE:

NOVARTIS TO HIGHLIGHT RHAPSIDO DATA ACROSS MULTIPLE IMMUNE-MEDIATED DISEASES AT EAACI CONGRESS 2026

BASEL, JUNE 4, 2026  NOVARTIS REPORTED FINAL 2.5-YEAR PHASE III ALIGN RESULTS SHOWING SLOWER KIDNEY FUNCTION DECLINE WITH VANRAFIA(ATRASENTAN) VERSUS PLACEBO IN ADULTS WITH IGA NEPHROPATHY (IGAN)1 ,2. RESULTS WERE PUBLISHED IN THE LANCET AND PRESENTED AT THE EUROPEAN RENAL ASSOCIATION (ERA) CONGRESS. ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) CHANGE FROM BASELINE FAVORED VANRAFIA, ALONGSIDE SUSTAINED REDUCTIONS OF PROTEIN IN THE URINE THROUGH END OF TREATMENT. BENEFITS WERE CONSISTENT ACROSS DIFFERENT MEASURES OF KIDNEY FUNCTION AND IN PATIENTS ADDITIONALLY RECEIVING SODIUM-GLUCOSE CO-TRANSPORTER-2 (SGLT2) INHIBITORS1,2. THESE RESULTS PROVIDE ROBUST EVIDENCE OF CLINICALLY MEANINGFUL SLOWING OF KIDNEY FUNCTION DECLINE OVER MORE THAN TWO YEARS OF TREATMENT, REINFORCING FINDINGS FROM THE EARLIER ANALYSIS OF PROTEINURIA REDUCTION, SAID RICHARD LAFAYETTE, MD, FACP, PROFESSOR OF MEDICINE, NEPHROLOGY, DIRECTOR OF THE GLOMERULAR DISEASE CENTER AT STANFORD UNIVERSITY MEDICAL CENTER, AND ALIGN STUDY INVESTIGATOR AND STEERING COMMITTEE MEMBER. THEY HIGHLIGHT THE ROLE OF A HIGHLY SELECTIVE ENDOTHELIN A RECEPTOR ANTAGONIST AS PART OF AN EVOLVING TREATMENT APPROACH FOR IGAN.

NOVARTIS IGAN DATA IN THE LANCET SHOW CLINICALLY MEANINGFUL SLOWING OF KIDNEY FUNCTION DECLINE WITH VANRAFIA OVER 2.5 YEARS

BASEL, JUNE 3, 2026  NOVARTIS PRESENTED TODAY NEW COSENTYX (SECUKINUMAB) DATA IN POLYMYALGIA RHEUMATICA (PMR) DEMONSTRATING A STATISTICALLY SIGNIFICANT, CLINICALLY MEANINGFUL DIFFERENCE IN SUSTAINED REMISSION RATES VS PLACEBO AND SIGNIFICANT STEROID SPARING8. PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE AND SIMULTANEOUSLY PRESENTED AT THE 2026 EUROPEAN ALLIANCE OF ASSOCIATIONS FOR RHEUMATOLOGY (EULAR) CONGRESS, PHASE III REPLENISH DATA SHOWED THAT THE EFFECT OF COSENTYX TREATMENT WAS SUSTAINED THROUGH WEEK 52 IN THIS INVESTIGATIONAL USE8.

NOVARTIS COSENTYX PMR DATA IN NEW ENGLAND JOURNAL OF MEDICINE SHOWED SUSTAINED REMISSION VS PLACEBO IN TWICE AS MANY PATIENTS

BASEL, JUNE 1, 2026  NOVARTIS WILL PRESENT NEW DATA FROM 31 ABSTRACTS ACROSS ITS INDUSTRY-LEADING IMMUNOLOGY PORTFOLIO AT THE EUROPEAN ALLIANCE OF ASSOCIATIONS FOR RHEUMATOLOGY (EULAR) CONGRESS ON JUNE 3-6 IN LONDON, ADVANCING SCIENTIFIC INSIGHT INTO HIGH-BURDEN AUTOIMMUNE DISEASES.

NOVARTIS DATA AT EULAR 2026 DEMONSTRATES MOMENTUM FOR BROAD IMMUNOLOGY PORTFOLIO FOR COMPLEX, HIGH UNMET NEED DISEASES

BASEL, MAY 31, 2026  NOVARTIS TODAY ANNOUNCED RESULTS SHOWING CONSISTENT RADIOGRAPHIC PROGRESSION-FREE SURVIVAL (RPFS) IMPROVEMENT ACROSS KEY SUBGROUPS WITH PLUVICTO (LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN) PLUS STANDARD OF CARE (SOC; ANDROGEN RECEPTOR PATHWAY INHIBITOR [ARPI] + ANDROGEN DEPRIVATION THERAPY [ADT]) COMPARED TO SOC ALONE IN PSMA-POSITIVE METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC). THESE PSMADDITION DATA WERE PRESENTED AS AN ORAL PRESENTATION AT THE 2026 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING.

Novartis AG

NVS

Price

Financial Reports

No items found.

Press Releases

Novartis AG

NVS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

NVS